AJANTPHARM Ajanta Pharma Q3 FY26 results (Oct–Dec 2025) and concall
Ajanta Pharma delivered a strong Q3 FY26 performance, characterized by robust growth in the US and India markets, which offset temporary softness in Asia. The company maintained high profitability with an EBITDA margin of 28% and a PAT margin of 20%. Management remains confident in its mid-teens annual growth guidance, supported by a healthy product pipeline and strategic expansions into new therapies like Gynaecology and GLP-1 generics.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 400.0%, net profit up 17.6% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|
| Revenue | 4 | 11 | 14 | 14 | 20 +400% |
| EBITDA | 321 | 297 | 351 | 328 | 382 +19% |
| Net profit | 233 | 225 | 255 | 260 | 274 +18% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
